PD184352 (CI-1040)

Catalog No.S1020

Molecular Weight(MW): 478.67

PD184352 (CI-1040) is an ATP non-competitive MEK1/2 inhibitor with IC50 of 17 nM in cell-based assays, 100-fold more selective for MEK1/2 than MEK5. Phase 2.

Cited by 69 Publications

Cancer Discov, 2016, 6(8):838-851

PubMed: 27179038 ( click the link to review the publication )

Cancer Cell, 2016, 10.1016/j.ccell.2016.01.006

PubMed: 26859455 ( click the link to review the publication )

Cancer Discov, 2013, 3(9):1058-71

PubMed: 23744832 ( click the link to review the publication )

Cancer Discov, 2012, 2(10):934-47

PubMed: 22961667 ( click the link to review the publication )

Science, 2011, 331(6019):912-6

PubMed: 21330545 ( click the link to review the publication )

Nat Genet, 2011, 44(2):133-9

PubMed: 22197931 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(6):778-790

PubMed: 31160710 ( click the link to review the publication )

Mol Cell, 2019, 74(5):1086-1102.e5

PubMed: 31101498 ( click the link to review the publication )

Cell Rep, 2019, 28(9):2358-2372

PubMed: 31461652 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):322

PubMed: 31331377 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2019, 32(2):280-291

PubMed: 30277012 ( click the link to review the publication )

Cell Death Dis, 2019, 10(12):871

PubMed: 31740667 ( click the link to review the publication )

EMBO Rep, 2018, 19(2):320-336

PubMed: 29263201 ( click the link to review the publication )

Elife, 2018, 10.7554/eLife.40167

PubMed: 30561326 ( click the link to review the publication )

Sci Rep, 2018, 8(1):18043

PubMed: 30575780 ( click the link to review the publication )

Cancer Res, 2017, 77(5):1212-1226

PubMed: 28087600 ( click the link to review the publication )

J Hematol Oncol, 2017, 10(1):19

PubMed: 28100259 ( click the link to review the publication )

FASEB J, 2017, 31(5):1903-1915

PubMed: 28174207 ( click the link to review the publication )

Antiviral Res, 2017, 142:178-184

PubMed: 28377100 ( click the link to review the publication )

Biochem Pharmacol, 2017, 136:40-50

PubMed: 28404378 ( click the link to review the publication )

Methods Mol Biol, 2017, 1487:163-174

PubMed: 27924566 ( click the link to review the publication )

Elife, 2016, 10.7554/eLife.11414

PubMed: 26999821 ( click the link to review the publication )

Cell Mol Immunol, 2016, 13(5):658-68

PubMed: 26189368 ( click the link to review the publication )

Drug Metab Dispos, 2016, 44(5):665-71

PubMed: 26953171 ( click the link to review the publication )
Oncol Lett, 2016, 11(1):99-104

PubMed: 26870175 ( click the link to review the publication )

Eur Rev Med Pharmacol Sci, 2016, 20(10):1961-8

PubMed: 27249593 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2015.12

PubMed: 25684139 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1711

PubMed: 25837487 ( click the link to review the publication )

Anim Reprod Sci, 2015, 161:47-57

PubMed: 26307658 ( click the link to review the publication )

Cytometry A, 2015, 10.1002/cyto.a.22628

PubMed: 25598437 ( click the link to review the publication )

eNeuro, 2015, 2(5)

PubMed: 26730399 ( click the link to review the publication )

J Clin Invest, 2014, 124(7):3016-31

PubMed: 24937430 ( click the link to review the publication )

EMBO Mol Med, 2014, 7(1):102-23

PubMed: 25550395 ( click the link to review the publication )

Cancer Lett, 2014, 347(2):212-24

PubMed: 24576622 ( click the link to review the publication )

Cancer Lett, 2014, 348(1-2):38-49

PubMed: 24650799 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1445

PubMed: 25299770 ( click the link to review the publication )

FASEB J, 2014, 28(10):4551-62

PubMed: 25008089 ( click the link to review the publication )

Mol Cell Proteomics, 2014, 13(6):1429-38

PubMed: 24643969 ( click the link to review the publication )

Biochem J, 2014, 459(3):513-24

PubMed: 24527759 ( click the link to review the publication )

Virology, 2014, 468-470C:490-503

PubMed: 25261871 ( click the link to review the publication )

BMC Cancer, 2014, 14(1):240

PubMed: 24708867 ( click the link to review the publication )

PLoS One, 2014, 9(12):e114389

PubMed: 25486532 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(20):5749-57

PubMed: 23948972 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(20):5749-57

PubMed: 23948972 ( click the link to review the publication )

Cancer Res, 2013, 73(20):6346-58

PubMed: 23966295 ( click the link to review the publication )

Dis Model Mech, 2013, 6(2):521-9

PubMed: 22996645 ( click the link to review the publication )

PLoS One, 2013, 8(10):e76505

PubMed: 24124570 ( click the link to review the publication )

PLoS One, 2013, 8(9):e73548

PubMed: 24019927 ( click the link to review the publication )
PLoS One, 2013, 8(7):e68378

PubMed: 23874604 ( click the link to review the publication )

J Natl Cancer Inst, 2012, 104(21):1673-9

PubMed: 22997239 ( click the link to review the publication )

Oncogene, 2012, 32(38):4480-9

PubMed: 23108403 ( click the link to review the publication )

Breast Cancer Res, 2012, 14(4):R111

PubMed: 22817771 ( click the link to review the publication )

Neoplasia, 2012, 14(4):283-96

PubMed: 22577344 ( click the link to review the publication )

J Biol Chem, 2012, 288(6):4174-93

PubMed: 23255592 ( click the link to review the publication )

J Biol Chem, 2012, 287(33):27863-75

PubMed: 22685289 ( click the link to review the publication )

Mol Endocrinol, 2012, 26(6):1056-73

PubMed: 22570334 ( click the link to review the publication )

Int J Parasitol, 2012, 40(5):555-67

PubMed: 19887070 ( click the link to review the publication )

J Cell Biochem, 2012, 113(1):360-71

PubMed: 21928324 ( click the link to review the publication )

J Biomol Screen, 2012, 17(6):813-21

PubMed: 22453235 ( click the link to review the publication )

J Exp Med, 2011, 208(9):1889-900

PubMed: 21825016 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2011, 108(39):16392-7

PubMed: 21930937 ( click the link to review the publication )

Cell Death Dis, 2011, 2:e124

PubMed: 21368895 ( click the link to review the publication )

Neoplasia, 2011, 13(2):154-66

PubMed: 21403841 ( click the link to review the publication )

Dis Model Mech, 2011, 4(3):393-9

PubMed: 21263000 ( click the link to review the publication )

Antiviral Res, 2011, 92(2):195-203

PubMed: 21854809 ( click the link to review the publication )

Toxicol Sci, 2011, 123(2):542-9

PubMed: 21742783 ( click the link to review the publication )

Front Physiol, 2011, 2:71

PubMed: 22028692 ( click the link to review the publication )

Sci Signal, 2010, 3(149):ra84

PubMed: 21098728 ( click the link to review the publication )

Methods Mol Biol, 2010, 661:107-22

PubMed: 20811979 ( click the link to review the publication )

Purity & Quality Control

Choose Selective MEK Inhibitors

Biological Activity

Description

PD184352 (CI-1040) is an ATP non-competitive MEK1/2 inhibitor with IC50 of 17 nM in cell-based assays, 100-fold more selective for MEK1/2 than MEK5. Phase 2.

Features

First MEK inhibitor to begin clinical development.

Targets

MEK1 ^[1] (Cell-free assay)	MEK2 ^[1] (Cell-free assay)
17 nM	17 nM

In vitro

CI-1040 treatment produces a reduction of pMAPK levels in multiple tumor cells including Colon 26, BX-PC3 pancreatic, A431 cervical, HT-29 colon, ZR-25-1 breast and SKOV-3 ovarian carcinomas. CI-1040 treatment doesn't inhibit the phosphorylation of Jun kinase, p38 kinase or Akt, indicating CI-1040 specifically targets MEK. Inhibition of MAPK activation by CI-1040 prevents cell cycle progression and induces a G1 block. ^[1] The IC50 for inhibition of MEK1 by CI-1040 is 0.3 μM, 15-fold higher than the concentration required to inhibit the EGF-induced activation of ERK2 in Swiss 3T3 cells. These results indicate CI-1040 exerts its effects on cells by suppressing the activation of MKK1, and not by blocking its activity. 2 nM PD184352 inhibits the activation of MKK1 in Swiss 3T3 cells by 50%, while over 100-fold concentration of CI-1040 inhibits MEK1 in vitro. PD184352 also inhibits the Raf-catalysed phosphorylation of MEK1 without any effect on the Raf-catalysed phosphorylation of myelin basic protein. ^[2] CI-1040 inhibits 86% of papillary thyroid carcinoma (PTC) cell growth with the RET/PTC1 rearrangement at 10μM compared with cells treated with DMSO only. CI-1040 shows potent inhibition to PTC cells (BRAF mutation) with GI50 of 52 nM, but low activity to RET/PTC1 rearrangement type with GI50 of 1.1 μM. ^[3] A recent research indicates CI-1040 increases the apoptotic effect of BMS-214662 in a CML blast crisis cell line, K562, and in primary chronic phase CD34+ CML cells. ^[4]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
H9	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXfJR\|UxRTBwMEKyO\|Yh\|ryP	MV\TRW5ITVJ?
CHP-212	NFPLdnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{PGNmlEPTB;MD6wNlg5PSEQvF2=	MYTTRW5ITVJ?
EoL-1-cell	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUnJR\|UxRTBwMESxOVIh\|ryP	NYDiOWFsW0GQR1XS
DU-4475	MoLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnHFTWM2OD1yLkC3OVk6KM7:TR?=	MXzTRW5ITVJ?
MMAC-SF	MlTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MknDTWM2OD1yLkGwPVc1KM7:TR?=	M1fwfXNCVkeHUh?=
AGS	MmqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1n6RWlEPTB;MD6xNVcyOyEQvF2=	NHzZXXNUSU6JRWK=
M14	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3[3U2lEPTB;MD6xOVQ3QCEQvF2=	M2H1N3NCVkeHUh?=
CP50-MEL-B	M3PGSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXXJR\|UxRTBwMUeyOVQh\|ryP	NV3Nd\|BXW0GQR1XS
C32	NXGwOYRIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUPJR\|UxRTBwMUmwO\|Ih\|ryP	NIq4OIdUSU6JRWK=
KMOE-2	M4XJW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{i2WGlEPTB;MD6xPVc6PSEQvF2=	M1rJeHNCVkeHUh?=
A101D	NUfQ[3VOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Moe1TWM2OD1yLkKxOEDPxE1?	MYXTRW5ITVJ?
KM12	M3vOcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M37rfGlEPTB;MD6yOFA2PyEQvF2=	MULTRW5ITVJ?
HSC-4	NITp[FZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkfETWM2OD1yLkK0N\|k2KM7:TR?=	NEP5OFdUSU6JRWK=
NOMO-1	NGDSXGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUjJR\|UxRTBwMkW3OFIh\|ryP	MWnTRW5ITVJ?
MZ7-mel	NGrXPVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX;JR\|UxRTBwMk[zOEDPxE1?	M3[1XHNCVkeHUh?=
ACN	NGjMeW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXvjR2d{UUN3ME2wMlI3PzN5IN88US=>	M3HZPHNCVkeHUh?=
MEL-HO	NWTNN3ZvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1jzZWlEPTB;MD6yO\|Y2OiEQvF2=	MULTRW5ITVJ?
BHT-101	M{nWeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXjveY91UUN3ME2wMlI5PjB4IN88US=>	M1uyNXNCVkeHUh?=
SK-MEL-28	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFHNR4RKSzVyPUCuN\|A1ODlizszN	Moi0V2FPT0WU
KG-1	NWDhbFNTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVLJR\|UxRTBwM{C2Olgh\|ryP	NF\IVYhUSU6JRWK=
COLO-679	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVzwb5FbUUN3ME2wMlMzPzJizszN	MXTTRW5ITVJ?
SK-MEL-24	NX32emNuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmHrTWM2OD1yLkOyPFE{KM7:TR?=	NEHEe29USU6JRWK=
G-361	M1jpb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1rlOWlEPTB;MD6zOlc6PSEQvF2=	NXHUclRPW0GQR1XS
KY821	NYjFfIVvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGe0XolKSzVyPUCuN\|c6OSEQvF2=	M1TYNXNCVkeHUh?=
KASUMI-1	NIW1RXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVfHRW9CUUN3ME2wMlM6QSEQvF2=	NInjbWNUSU6JRWK=
HL-60	NW\KSpBJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnLHTWM2OD1yLkSxNVA4KM7:TR?=	NFz2TZRUSU6JRWK=
K5	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGnvSoFKSzVyPUCuOFMyOTdizszN	MofaV2FPT0WU
KU812	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXzpWGR1UUN3ME2wMlQ2Ojl7IN88US=>	M1fQSnNCVkeHUh?=
SH-4	NWjtZYo5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3nYfGlEPTB;MD60OlI2PiEQvF2=	M{fGUnNCVkeHUh?=
HTC-C3	M13WU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYDJR\|UxRTBwNE[1N\|Eh\|ryP	M2jV[nNCVkeHUh?=
CP66-MEL	M4naZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoLZTWM2OD1yLkS4PFA6KM7:TR?=	Mn\sV2FPT0WU
WM-115	Mn7ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXvJR\|UxRTBwNEmyOVch\|ryP	MVLTRW5ITVJ?
A2780	NF;EcXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NE\BU2JKSzVyPUCuOFk5OjNizszN	NIDmNmVUSU6JRWK=
P12-ICHIKAWA	NUH5TIJxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGPPdlJKSzVyPUCuOlEzOjFizszN	MlnyV2FPT0WU
HMV-II	M1f1UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoK5TWM2OD1yLk[0OFY2KM7:TR?=	NFHMWZZUSU6JRWK=
HT-144	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkTvTWM2OD1yLk[0OlU4KM7:TR?=	Mk\CV2FPT0WU
LB2518-MEL	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3LQRmlEPTB;MD63NVY{OiEQvF2=	M33JRnNCVkeHUh?=
NCI-SNU-1	NUfyVm9TT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1y1dGlEPTB;MD63OVQ{OyEQvF2=	NVfjb4I1W0GQR1XS
C2BBe1	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4D3VGlEPTB;MD64NVAzOyEQvF2=	MmnOV2FPT0WU
PSN1	NX\KOo5PT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NG\se5VKSzVyPUCuPVYyQTZizszN	Mn7LV2FPT0WU
UACC-257	Ml70S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVLJR\|UxRTBwOU[0O\|Mh\|ryP	NXPkO\|JCW0GQR1XS
RVH-421	MoHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXjJR\|UxRTBwOUexPEDPxE1?	MW\TRW5ITVJ?
GP5d	NEL0eZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{HuN2lEPTB;MD65PFMxQCEQvF2=	MY\TRW5ITVJ?
TYK-nu	NF;2UHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmDtTWM2OD1zLkCzNVczKM7:TR?=	M2jDdnNCVkeHUh?=
SK-N-AS	M3m3dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXrJR\|UxRTFwMEe5OFch\|ryP	MYjTRW5ITVJ?
SW620	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFHpdXdKSzVyPUGuNVM2OzRizszN	NX\VOnNoW0GQR1XS
HuP-T4	NVvZdpFPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUTJR\|UxRTFwMUizOVkh\|ryP	NV;0XFRFW0GQR1XS
A549	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlLXTWM2OD1zLkG5OVc3KM7:TR?=	MoXsV2FPT0WU
Mewo	NX65ZZB[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVXQS4dDUUN3ME2xMlIxOjd4IN88US=>	M4T2fnNCVkeHUh?=
ONS-76	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEewS2JKSzVyPUGuNlIxPDlizszN	M2PWXHNCVkeHUh?=
SK-MEL-1	MlK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml3YTWM2OD1zLkKzOFE6KM7:TR?=	NIPHNGhUSU6JRWK=
RCM-1	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHL3VoNKSzVyPUGuNlQxPDdizszN	MmPjV2FPT0WU
H-EMC-SS	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGXJbYlKSzVyPUGuNlk3ODhizszN	MYrTRW5ITVJ?
NCI-H2291	Ml\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlXZTWM2OD1zLkOyOVM3KM7:TR?=	NVnoUFQ2W0GQR1XS
SW1463	NXXzbnpVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWHURnVuUUN3ME2xMlM{PzJzIN88US=>	M3T1b3NCVkeHUh?=
LS-411N	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYrGb2hUUUN3ME2xMlQxPTF5IN88US=>	NFnMSIJUSU6JRWK=
BV-173	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1LFU2lEPTB;MT60OFAyPSEQvF2=	M3e5XnNCVkeHUh?=
LS-513	MlXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUDQZpZMUUN3ME2xMlQ2OTl{IN88US=>	NEHN[XFUSU6JRWK=
LoVo	MoqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUnLZXJVUUN3ME2xMlQ3Ozl7IN88US=>	MXfTRW5ITVJ?
HO-1-N-1	NES4PFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFn5ZpFKSzVyPUGuOVE3OzRizszN	M1G4RnNCVkeHUh?=
ML-2	MnG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVPxRpNGUUN3ME2xMlUzQDZ6IN88US=>	NXTkXYpPW0GQR1XS
NCI-H1437	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUPJR\|UxRTFwNUWyO\|Uh\|ryP	M{jsV3NCVkeHUh?=
SW1116	NWrwTHpMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnPwTWM2OD1zLkW2N\|k5KM7:TR?=	NH;tRnhUSU6JRWK=
A4-Fuk	NX;RSno{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEOxOFNKSzVyPUGuOVcxPDVizszN	Mn60V2FPT0WU
HD-MY-Z	NWX4d5VTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2r0NmlEPTB;MT61O\|M4PiEQvF2=	Mn\pV2FPT0WU
SK-MEL-2	NV[xTldXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVH1W5dDUUN3ME2xMlU4PDV7IN88US=>	M1;5bHNCVkeHUh?=
RT-112	NF[0[ZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NELEbXlKSzVyPUGuOVg6PTJizszN	NIHlbVVUSU6JRWK=
COLO-829	NGWyNHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVjJR\|UxRTFwNkKyN\|Ih\|ryP	NHjQcGdUSU6JRWK=
OVCAR-5	M2q2eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnjOTWM2OD1zLke3Olg4KM7:TR?=	NFP4WHVUSU6JRWK=
NB69	NEf0ZplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn\wTWM2OD1zLke4OFY6KM7:TR?=	MWjTRW5ITVJ?
NCI-H292	NEnYfJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnGzTWM2OD1zLki2Olk6KM7:TR?=	M2\RfXNCVkeHUh?=
LOXIMVI	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1;3UGlEPTB;MT64PVQzPyEQvF2=	NUHzdolYW0GQR1XS
BPH-1	M{LuWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnjsTWM2OD1zLki5OVkyKM7:TR?=	NHTOVoxUSU6JRWK=
A375	M3nGRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYDJR\|UxRTFwOEm3NVQh\|ryP	Mn;LV2FPT0WU
LCLC-97TM1	NF3RR5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1viU2lEPTB;MT65NlI2PiEQvF2=	NVe5ZVZlW0GQR1XS
RXF393	MmT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M133PWlEPTB;MT65O\|g5PyEQvF2=	MUjTRW5ITVJ?
HCC70	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWfabHFVUUN3ME2yMlAzPDJ4IN88US=>	NVvLRlNGW0GQR1XS
EM-2	NFjXWI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NELWepBKSzVyPUKuNFcyQThizszN	NIjqRVhUSU6JRWK=
MZ2-MEL	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX\JR\|UxRTJwMUGxNlch\|ryP	MVTTRW5ITVJ?
HN	M4fRWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlrrTWM2OD1{LkG2Nlc5KM7:TR?=	MoG3V2FPT0WU
A2058	NHLBUGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmXVTWM2OD1{LkG5Nlc6KM7:TR?=	MWXTRW5ITVJ?
NB7	M1G3[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkmxTWM2OD1{LkO0NFg3KM7:TR?=	M1P1XXNCVkeHUh?=
DOK	MlPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mny1TWM2OD1{LkO1O\|c{KM7:TR?=	NF34blNUSU6JRWK=
CAL-27	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEG2TodKSzVyPUKuN\|kzOzZizszN	NE\rZWpUSU6JRWK=
BB65-RCC	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYTJR\|UxRTJwNEC2O\|Qh\|ryP	M4\i[XNCVkeHUh?=
RD	NXm5PW9[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV\hbpByUUN3ME2yMlQ1PzJ\|IN88US=>	M1rpdHNCVkeHUh?=
KNS-62	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVLJR\|UxRTJwNUGxOlQh\|ryP	M{\pdnNCVkeHUh?=
EW-13	MnXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGXpNllKSzVyPUKuOVY{OzlizszN	M4rJR3NCVkeHUh?=
DB	NH7zcJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkTNTWM2OD1{LkW4O\|g5KM7:TR?=	MlzrV2FPT0WU
HCC2218	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnfmTWM2OD1{Lk[0O\|c5KM7:TR?=	M2XWUXNCVkeHUh?=
L-363	NIe4XoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVqzPYVpUUN3ME2yMlc1OzdizszN	M4fDS3NCVkeHUh?=
CHL-1	NWD1boFsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXLkfolkUUN3ME2yMlgxPzh3IN88US=>	NWXYV3FlW0GQR1XS
BFTC-905	MlXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX7hZoVDUUN3ME2yMlgzPTNizszN	NXXCO3ZIW0GQR1XS
HCE-T	MnvIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHHGPGhKSzVyPUKuPFMzPjRizszN	M{fB[HNCVkeHUh?=
COLO-792	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVTJR\|UxRTJwOESwNlch\|ryP	MkjPV2FPT0WU
LB2241-RCC	NH\Nbo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVjJR\|UxRTJwOEW4PVMh\|ryP	M3vqN3NCVkeHUh?=
CAL-39	MoL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkD0TWM2OD1{Lki5PVk6KM7:TR?=	NXPTXZBiW0GQR1XS
T-24	NH;ld5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NE\lfGVKSzVyPUKuPVEyOTJizszN	MY\TRW5ITVJ?
NCI-H727	M3\aNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXrNdWlmUUN3ME2yMlkyPzl4IN88US=>	MmnsV2FPT0WU
Ca9-22	M{m0Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4nKSWlEPTB;Mj65O\|I2PSEQvF2=	NFS3XWZUSU6JRWK=
MIA-PaCa-2	MnHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYCwcYRYUUN3ME2zMlAxPzhzIN88US=>	NYXIR\|BEW0GQR1XS
HT-1080	MoTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXXJR\|UxRTNwMEG5PVch\|ryP	NFLKTm5USU6JRWK=
D-423MG	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3;DdmlEPTB;Mz6wO\|c2OyEQvF2=	MX7TRW5ITVJ?
LAMA-84	NIHnZpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4PFRmlEPTB;Mz6xN\|U5KM7:TR?=	M3LKbHNCVkeHUh?=
SW780	NWHueHBKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3frSWlEPTB;Mz6xOFIzQSEQvF2=	MVjTRW5ITVJ?
KU-19-19	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlvQTWM2OD1\|LkG3NFM1KM7:TR?=	M1O5fnNCVkeHUh?=
COLO-741	NYS5UGQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHPCdYZKSzVyPUOuNVg3PzNizszN	MXXTRW5ITVJ?
HSC-3	NH7I[GJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWP1bpYzUUN3ME2zMlI{OTVzIN88US=>	M1TLVnNCVkeHUh?=
SN12C	MkXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn3NTWM2OD1\|LkK0O\|AyKM7:TR?=	NYXJVVV1W0GQR1XS
786-0	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mon1TWM2OD1\|LkK3NlQ{KM7:TR?=	MkHkV2FPT0WU
GAK	NY\1TnRVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWPJR\|UxRTNwM{K1OlEh\|ryP	M37p[XNCVkeHUh?=
PANC-03-27	M{fDXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mnu1TWM2OD1\|LkO1NFQ2KM7:TR?=	Mo[zV2FPT0WU
CTB-1	M336e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVnDVodvUUN3ME2zMlQ4ODR5IN88US=>	MmDKV2FPT0WU
A427	NWrrRmVNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWfUclNbUUN3ME2zMlU6PTV4IN88US=>	NHXLXW1USU6JRWK=
EGI-1	MkCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWfJR\|UxRTNwNkC1PFMh\|ryP	NYfzW2loW0GQR1XS
U-2-OS	Ml[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MU\JR\|UxRTNwNkeyOVYh\|ryP	MoTjV2FPT0WU
NCI-SNU-5	NHXJOXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWW5b3I{UUN3ME2zMlY4PzNizszN	Mk\ZV2FPT0WU
SK-LU-1	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mo[0TWM2OD1\|Lk[4O\|k5KM7:TR?=	NXTiSlZ2W0GQR1XS
697	NG[1UFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mnq4TWM2OD1\|Lk[5OlA{KM7:TR?=	NGXG[4FUSU6JRWK=
HPAF-II	MkOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVjJR\|UxRTNwN{W0PUDPxE1?	MXLTRW5ITVJ?
NCI-H2087	NFm5[nhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX2ycFBLUUN3ME2zMlg1Pjd{IN88US=>	NGe2WnRUSU6JRWK=
SK-MEL-3	NEL0WVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlfDTWM2OD1\|Lki1NVU1KM7:TR?=	NGnPRW1USU6JRWK=
CGTH-W-1	NIDQUmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVLJR\|UxRTNwOEW3NlUh\|ryP	MnrzV2FPT0WU
8505C	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYnyNmQ{UUN3ME2zMlkxODd6IN88US=>	M2LVeXNCVkeHUh?=
GAMG	MlTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX3o[WxKUUN3ME20MlAzOzd5IN88US=>	MWPTRW5ITVJ?
SW626	M4TJSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NE[zRZRKSzVyPUSuNFQ1QCEQvF2=	M3;IdnNCVkeHUh?=
CAL-62	MknoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVTJR\|UxRTRwMEe0N{DPxE1?	MmO0V2FPT0WU
MHH-PREB-1	NFjD[olIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGnkOHhKSzVyPUSuNVIyOTFizszN	MXLTRW5ITVJ?
RPMI-7951	MoLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFS1clJKSzVyPUSuNlU2QDlizszN	NH;0O3JUSU6JRWK=
HOP-92	NXfXOmVDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1TLcWlEPTB;ND6yOVY4KM7:TR?=	M4HOcnNCVkeHUh?=
MDA-MB-231	MnvrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX\nTIJKUUN3ME20MlI6OjJ\|IN88US=>	MUPTRW5ITVJ?
LAN-6	MnLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MofnTWM2OD12LkOxOlM4KM7:TR?=	M{PBZ3NCVkeHUh?=
ALL-PO	Mnu0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGezeoNKSzVyPUSuN\|YyPTZizszN	MlnzV2FPT0WU
HH	Ml70S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV\obY5UUUN3ME20MlQyPTl5IN88US=>	NEDROFZUSU6JRWK=
IGROV-1	MnmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M176R2lEPTB;ND60OVE4OSEQvF2=	MYHTRW5ITVJ?
NCI-H358	Ml;4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYPIOWdsUUN3ME20MlQ2Ozh3IN88US=>	MnezV2FPT0WU
NB5	NYj5dVljT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVvNNnI4UUN3ME20MlYxOzZ7IN88US=>	NE\5[opUSU6JRWK=
NCI-H747	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4LXUWlEPTB;ND62PFgxPyEQvF2=	Mm\qV2FPT0WU
NH-12	NV;yWFVwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFTXVpVKSzVyPUSuO\|E3OjVizszN	NGSxN49USU6JRWK=
LB1047-RCC	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmfqTWM2OD12LkezPFE2KM7:TR?=	NHT2b4RUSU6JRWK=
EFO-27	Mk\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1jxcGlEPTB;ND63PFY3PyEQvF2=	MYrTRW5ITVJ?
EPLC-272H	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mnv2TWM2OD12Lkm5OlY6KM7:TR?=	MX;TRW5ITVJ?
CAL-54	M4nzU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX7JR\|UxRTVwMEK2PVUh\|ryP	NUD3TXZMW0GQR1XS
H4	MljhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXXJR\|UxRTVwMESyOVUh\|ryP	M4jYfXNCVkeHUh?=
MOLT-13	M4rySmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUfJR\|UxRTVwME[3O\|Yh\|ryP	MY\TRW5ITVJ?
CAL-33	M1r5bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmXzTWM2OD13LkGyN\|E4KM7:TR?=	MVrTRW5ITVJ?
23132-87	NXfiWI9uT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{LpNGlEPTB;NT6xOlg4OiEQvF2=	M3LWW3NCVkeHUh?=
UM-UC-3	MonFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmfzTWM2OD13LkG4NFQ4KM7:TR?=	MVjTRW5ITVJ?
HuH-7	M3PUT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2jWUWlEPTB;NT6yO\|E1PyEQvF2=	NYP1SFJlW0GQR1XS
BCPAP	Mkj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1LocGlEPTB;NT6zNlk3QSEQvF2=	NYG2XYN{W0GQR1XS
AsPC-1	M17pOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlHuTWM2OD13LkO2O\|Y{KM7:TR?=	M3izZXNCVkeHUh?=
NCI-H1155	MnnNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVPQUZlkUUN3ME21MlQxODVzIN88US=>	M{\Be3NCVkeHUh?=
GT3TKB	NIHOOGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2e5XWlEPTB;NT60OlU6QCEQvF2=	NH;1TWVUSU6JRWK=
HCC2998	NW\1eJVrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHLuUm9KSzVyPUWuOFkyODlizszN	Mnm2V2FPT0WU
NUGC-3	M3[0Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXXJR\|UxRTVwNEmzNFIh\|ryP	MoXDV2FPT0WU
Hs-578-T	NW\uTHlpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXTJR\|UxRTVwNUO3PVQh\|ryP	MljOV2FPT0WU
FADU	MmLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYr2WJlZUUN3ME21MlU2PzJ4IN88US=>	NEHt[YxUSU6JRWK=
NBsusSR	Mlv2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1vIbGlEPTB;NT61O\|E2PSEQvF2=	MWHTRW5ITVJ?
ME-180	NXzERlBST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWLJR\|UxRTVwNUiwPVIh\|ryP	MljUV2FPT0WU
SW1710	M2C1WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVvJR\|UxRTVwNkG2OVQh\|ryP	NELzOIpUSU6JRWK=
HuP-T3	NUnZc4dkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MY\JR\|UxRTVwNkKwNlkh\|ryP	MmfrV2FPT0WU
HOS	NUDF[Y0zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYXDSI5WUUN3ME21MlYzQTJ\|IN88US=>	MVrTRW5ITVJ?
PA-1	NFr5c\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MorVTWM2OD13Lk[0NlY2KM7:TR?=	MmDrV2FPT0WU
LU-99A	NX7GPGlkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHqxT45KSzVyPUWuOlY1PTFizszN	NIm0ZlVUSU6JRWK=
RS4-11	NE\QZ4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{jERmlEPTB;NT62Olc4PSEQvF2=	MUPTRW5ITVJ?
TE-8	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHS4UWFKSzVyPUWuOlg2OzdizszN	NWPscWhPW0GQR1XS
RERF-LC-MS	NVvIVHVYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1e0XmlEPTB;NT62PFgxOyEQvF2=	Mkf2V2FPT0WU
MEL-JUSO	NEHZfnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUXLOIlmUUN3ME21Mlc{PzhizszN	MorFV2FPT0WU
SK-MES-1	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXPPOHhzUUN3ME21Mlg{PTJ6IN88US=>	NVn4bJhvW0GQR1XS
D-263MG	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV7YfmRwUUN3ME21Mlg5OzVzIN88US=>	NVOweWlHW0GQR1XS
NB10	NEfkeo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4rrfGlEPTB;NT64PVQ3KM7:TR?=	NHTrRYJUSU6JRWK=
SK-HEP-1	NI[1fG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NG\OfItKSzVyPUWuPVM1PzFizszN	M2rtdnNCVkeHUh?=
HT-29	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmHRTWM2OD13Lkm4NVE5KM7:TR?=	NEH0T3VUSU6JRWK=
KYSE-140	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4jEcGlEPTB;Nj6wNlE5OiEQvF2=	NXHsTJRVW0GQR1XS
NCI-H1666	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVPJR\|UxRTZwMEi0OlEh\|ryP	NUnlPVE5W0GQR1XS
NCI-H1304	NFnZUFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV\XWGdqUUN3ME22MlE6QTRizszN	MkHBV2FPT0WU
RPMI-8866	Mn3aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWnITZV6UUN3ME22MlIyOzF\|IN88US=>	NWn2cotLW0GQR1XS
MV-4-11	NIDyXJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MojCTWM2OD14LkKzNVk6KM7:TR?=	NFOwXZBUSU6JRWK=
A431	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn;zTWM2OD14LkK0Nlk3KM7:TR?=	NYrJ[3pMW0GQR1XS
PANC-10-05	MnLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYXJR\|UxRTZwMkizOlMh\|ryP	M1HKOnNCVkeHUh?=
TK10	M3TxZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVjJR\|UxRTZwM{K2NFQh\|ryP	M2DjPXNCVkeHUh?=
NCI-H1975	M{Du[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWqxdYJCUUN3ME22MlQ4OjF3IN88US=>	MYrTRW5ITVJ?
A172	NVGyOYZpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkLUTWM2OD14LkS5NVc3KM7:TR?=	M1j2Z3NCVkeHUh?=
D-566MG	NV7JRpVqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MonyTWM2OD14LkW0N\|A{KM7:TR?=	NWHGdGx6W0GQR1XS
NCI-H2122	MmX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYLJR\|UxRTZwNkG1Nlgh\|ryP	MkHwV2FPT0WU
COR-L105	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXPJR\|UxRTZwNkWyO\|Uh\|ryP	M2Xm[XNCVkeHUh?=
AN3-CA	MoLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX7ydHg{UUN3ME22MlY5PjRzIN88US=>	NUP1fGwzW0GQR1XS
Calu-6	MkG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV\0WGIzUUN3ME22Mlc6Pjl6IN88US=>	NEDpTJFUSU6JRWK=
HCT-116	NWr4WlNXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml\UTWM2OD14LkixNlY1KM7:TR?=	MXzTRW5ITVJ?
MHH-NB-11	MmK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4jU[WlEPTB;Nj64OVAxOiEQvF2=	Ml\RV2FPT0WU
MFE-280	M3fDdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVXJR\|UxRTZwOEW5PFMh\|ryP	NGLXeGNUSU6JRWK=
SW1088	NUDEfnlMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGTEU4tKSzVyPU[uPVE6OTNizszN	NFuxOYNUSU6JRWK=
SW48	M1\WNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2ezSGlEPTB;Nj65OFUyKM7:TR?=	M1LNW3NCVkeHUh?=
HuCCT1	Ml3uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mlm0TWM2OD15LkCxNFM4KM7:TR?=	M4XGdnNCVkeHUh?=
ACHN	MlLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEX1PHhKSzVyPUeuNFI6PDNizszN	M3G5W3NCVkeHUh?=
8305C	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUjJR\|UxRTdwMEm5PVUh\|ryP	MXzTRW5ITVJ?
DoTc2-4510	M13wNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlvmTWM2OD15LkGyNVUh\|ryP	M4DEVnNCVkeHUh?=
COR-L23	NXi0bGEyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn:5TWM2OD15LkK0OFIh\|ryP	NW\v[Y1sW0GQR1XS
SK-MEL-30	NWLXfI1yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFK5V3ZKSzVyPUeuNlUxQDNizszN	MYPTRW5ITVJ?
BE-13	NX3kfW5CT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH:2PWxKSzVyPUeuN\|M5OzRizszN	MonlV2FPT0WU
GR-ST	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkDtTWM2OD15LkSwNVc1KM7:TR?=	NE[4eIVUSU6JRWK=
LU-135	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV;JR\|UxRTdwNUW5N\|kh\|ryP	MUXTRW5ITVJ?
U-266	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3nXfmlEPTB;Nz61OlI5PiEQvF2=	NFHUbVRUSU6JRWK=
NCI-H1355	NYDGPFhET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1eyNWlEPTB;Nz61PFY{PSEQvF2=	NGDFXZFUSU6JRWK=
NB14	MkHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MULJR\|UxRTdwNk[2OFIh\|ryP	M3\Fe3NCVkeHUh?=
SCC-25	NGHROJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3rWSWlEPTB;Nz63NFkh\|ryP	Mn7BV2FPT0WU
COLO-678	MmizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWLJW5dtUUN3ME23MlcyODd4IN88US=>	NX7k[oR{W0GQR1XS
TGBC1TKB	NFHhcVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{jCR2lEPTB;Nz64PVM6QCEQvF2=	M{j4dXNCVkeHUh?=
IST-MEL1	NUHWXmhlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYTJR\|UxRThwMEC0NFYh\|ryP	NGTMNYpUSU6JRWK=
ECC10	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3TpdmlEPTB;OD6wN\|M6PSEQvF2=	M1HJRnNCVkeHUh?=
EW-16	Mmm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M33NW2lEPTB;OD6wPFQ1PSEQvF2=	MV;TRW5ITVJ?
DOHH-2	M4fqXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4CyfWlEPTB;OD6yNFA6PSEQvF2=	MVzTRW5ITVJ?
NCI-H1581	NV7McmxqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkLDTWM2OD16LkK2N\|I{KM7:TR?=	NF\TTJNUSU6JRWK=
TE-5	MkDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3\qXGlEPTB;OD60NlQzQSEQvF2=	NIXx[I5USU6JRWK=
CAKI-1	MmTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3z0OmlEPTB;OD61O\|IzOiEQvF2=	MULTRW5ITVJ?
A673	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGqwR\|FKSzVyPUiuOlMzODJizszN	NGTjcHRUSU6JRWK=
CAL-12T	MnrlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWXJR\|UxRThwNkW3OVMh\|ryP	M2XuO3NCVkeHUh?=
DBTRG-05MG	M4Pxfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX\JR\|UxRThwN{S4OVkh\|ryP	NWfXUWlbW0GQR1XS
SK-N-FI	M3vZRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoLyTWM2OD16LkixN\|c6KM7:TR?=	MmDwV2FPT0WU
K-562	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWjJR\|UxRThwOEO5OVch\|ryP	MmrjV2FPT0WU
SBC-1	MmDOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIn5R\|NKSzVyPUiuPFY3PDVizszN	MXrTRW5ITVJ?
ES4	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUfJR\|UxRThwOE[4PFQh\|ryP	NXPieIljW0GQR1XS
MS-1	MkO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVPLN\|FpUUN3ME24Mlg4PTF5IN88US=>	NUnoOoQ4W0GQR1XS
RKO	Mnn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUT2S\|RlUUN3ME24Mlg6ODV5IN88US=>	MlLUV2FPT0WU
NCI-H1693	NGn1UWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlfpTWM2OD16LkmyNVch\|ryP	NGnBbmZUSU6JRWK=
SW954	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NInQ[\|JKSzVyPUiuPVY6PzhizszN	NYroO\|N[W0GQR1XS
SK-UT-1	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVrNRZJkUUN3ME24Mlk4Pjh\|IN88US=>	NIK3PXhUSU6JRWK=
T98G	MmXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWDrTZIxUUN3ME24Mlk6QDR4IN88US=>	MmDuV2FPT0WU
NCI-H2126	NWLvXYY3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{TZd2lEPTB;OT6wNFgzPiEQvF2=	NGXUOYRUSU6JRWK=
TE-12	NUjrWVBmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFzyWZNKSzVyPUmuNFM{PjdizszN	MmDJV2FPT0WU
DK-MG	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4X2WGlEPTB;OT6yNVE6OSEQvF2=	M1HUXXNCVkeHUh?=
MEG-01	NX60N5RwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1nyTGlEPTB;OT6yOFk{OSEQvF2=	NXHIc29vW0GQR1XS
HCC1937	NFnqPYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX3GUXRnUUN3ME25MlI6ODlzIN88US=>	NX3YN45nW0GQR1XS
MKN45	M3jGUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1yzV2lEPTB;OT60OVA3PSEQvF2=	NFLoRVFUSU6JRWK=
NCI-H1792	Ml7hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWPJR\|UxRTlwNEWyNVkh\|ryP	MlLLV2FPT0WU
SW1417	MleyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4P4dGlEPTB;OT61Olg{PyEQvF2=	MlnqV2FPT0WU
639-V	M2f4dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXTEO4JGUUN3ME25MlY1Ozh6IN88US=>	NGXKbZlUSU6JRWK=
P30-OHK	M3Kxcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4LVeWlEPTB;OT62OVMyPiEQvF2=	NGPQPJFUSU6JRWK=
YKG-1	M1TwN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWHJR\|UxRTlwN{WwN\|Mh\|ryP	M3jZRnNCVkeHUh?=
KGN	M2DIWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXnDN4hwUUN3ME25Mlg{Pzl3IN88US=>	M3mwXnNCVkeHUh?=
MSTO-211H	NH;3RYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIDrOYhKSzVyPUmuPVU2OjlizszN	Mk[yV2FPT0WU
NCI-H1573	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYPJR\|UxRTFyLkG1O\|Qh\|ryP	NXHxPYMzW0GQR1XS
NCI-H720	Mnn3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml[yTWM2OD1zMD6xPVg6KM7:TR?=	MVPTRW5ITVJ?
KARPAS-45	NXyyNFlST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4LicGlEPTB;MUCuNlc6PSEQvF2=	NGHNOpFUSU6JRWK=
MDA-MB-175-VII	M2PndWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIrJ[HZKSzVyPUGwMlQ5KM7:TR?=	MXvTRW5ITVJ?
SK-NEP-1	NU[1bpgzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUPJR\|UxRTFyLkS5PFEh\|ryP	MULTRW5ITVJ?
MKN28	NXrhR5M4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NY\pVZJ[UUN3ME2xNE42OThizszN	M{\Xc3NCVkeHUh?=
KYSE-520	NFLWS5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1rneWlEPTB;MUCuOVIh\|ryP	M4PlTXNCVkeHUh?=
KE-37	MkexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFf0e\|lKSzVyPUGwMlUzPzJizszN	MlHVV2FPT0WU
VA-ES-BJ	NXPF[o1lT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWPJR\|UxRTFyLkW2O{DPxE1?	NXzhVW9[W0GQR1XS
CCRF-CEM	MmnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4jsV2lEPTB;MUCuOVY5PCEQvF2=	MWLTRW5ITVJ?
GMS-10	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoPVTWM2OD1zMD62NFk1KM7:TR?=	MXPTRW5ITVJ?
NCI-H1623	NFHXXVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUjMOYY2UUN3ME2xNE43Ozd7IN88US=>	MXnTRW5ITVJ?
NEC8	M3HlT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkjCTWM2OD1zMD63O\|c{KM7:TR?=	M{PX[XNCVkeHUh?=
MOLT-16	NGjFTGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHH0eW9KSzVyPUGwMlgyOTNizszN	NWnEdndCW0GQR1XS
DJM-1	NXX0b5M4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mo[5TWM2OD1zMT6wN\|c6KM7:TR?=	M3jqUXNCVkeHUh?=
U251	M3u2c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4ewTmlEPTB;MUGuNFQzKM7:TR?=	MnWwV2FPT0WU
SBC-5	MnP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mmr2TWM2OD1zMT6xOFY4KM7:TR?=	M1\hWnNCVkeHUh?=
SW756	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH7jV4hKSzVyPUGxMlIyPTRizszN	MX\TRW5ITVJ?
KS-1	MkX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MknITWM2OD1zMT6yOlE6KM7:TR?=	NEDtVlVUSU6JRWK=
SF295	M3HEXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1nGNWlEPTB;MUGuN\|ExPCEQvF2=	NE\DeXNUSU6JRWK=
YH-13	MmmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYLreZk3UUN3ME2xNU4{OjZ5IN88US=>	NUDHTFdMW0GQR1XS
SW837	NXLyZWxzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MY\JR\|UxRTFzLkO1NFYh\|ryP	MkDDV2FPT0WU
KYSE-450	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXvJR\|UxRTFzLkSwOVch\|ryP	MUHTRW5ITVJ?
KYSE-180	MmS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUDJR\|UxRTFzLkS4NkDPxE1?	NXTGSJBKW0GQR1XS
S-117	NWHF[4tWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4DkU2lEPTB;MUGuOFg6PiEQvF2=	NUP4TYxOW0GQR1XS
KOSC-2	M124Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYTJR\|UxRTFzLk[yNlIh\|ryP	Mn;aV2FPT0WU
KYSE-270	MoH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{TvfmlEPTB;MUGuPFc1PSEQvF2=	M1qwO3NCVkeHUh?=
D-336MG	NW[4VHIyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWjJR\|UxRTFzLkmwO\|Uh\|ryP	MnXoV2FPT0WU
KALS-1	MlXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnnvTWM2OD1zMj6wNFE3KM7:TR?=	NXrpT4VbW0GQR1XS
LB373-MEL-D	M{TOZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVTJR\|UxRTF{LkC1N\|Mh\|ryP	Mn\aV2FPT0WU
HLE	NHjacG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1vNWGlEPTB;MUKuNFU5PSEQvF2=	M1GzeXNCVkeHUh?=
SJSA-1	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnrSTWM2OD1zMj6wO\|M2KM7:TR?=	NGDNXHRUSU6JRWK=
SW1990	M4fQU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoXBTWM2OD1zMj6wPVEyKM7:TR?=	M3XSOnNCVkeHUh?=
NOS-1	NHfGeJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFrQe\|dKSzVyPUGyMlE{PTJizszN	MlmwV2FPT0WU
GI-ME-N	NGe4SI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3[0Z2lEPTB;MUKuNlE3OyEQvF2=	MVjTRW5ITVJ?
NCI-H1703	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV[yUnNNUUN3ME2xNk4zPjF4IN88US=>	MkDDV2FPT0WU
ES7	NGXiUVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1m5PGlEPTB;MUKuNlczPCEQvF2=	NWXMNXAzW0GQR1XS
KYSE-510	MlO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVnJR\|UxRTF{LkWwO\|kh\|ryP	NVzt[lBNW0GQR1XS
BHY	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXfJR\|UxRTF{LkWzNFch\|ryP	MVjTRW5ITVJ?
TCCSUP	MoPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{XoV2lEPTB;MUKuOVc2PyEQvF2=	MoLCV2FPT0WU
HSC-2	NXXwdmViT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYLJR\|UxRTF{LkW5PVYh\|ryP	MYHTRW5ITVJ?
BEN	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH3Se5JKSzVyPUGyMlYyPDNizszN	Ml2wV2FPT0WU
769-P	MoP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVXJR\|UxRTF{Lke5NlQh\|ryP	MXPTRW5ITVJ?
HT	M3[1XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHrtT2hKSzVyPUGyMlg{PDZizszN	M13JdXNCVkeHUh?=
LXF-289	M{i2dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkT4TWM2OD1zMj65OVMyKM7:TR?=	Mon3V2FPT0WU
OVCAR-3	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3HKbGlEPTB;MUKuPVU3PyEQvF2=	NG[wRYhUSU6JRWK=
ATN-1	M3Xtb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3qyZmlEPTB;MUOuNFE5PCEQvF2=	MoPLV2FPT0WU
8-MG-BA	M161RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXPJR\|UxRTF\|LkC0OVUh\|ryP	MmjSV2FPT0WU
SW13	NUDSToxJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoDkTWM2OD1zMz6xNVY2KM7:TR?=	MUjTRW5ITVJ?
NCI-H1092	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGf6WHhKSzVyPUGzMlE3OiEQvF2=	MoTrV2FPT0WU
OAW-42	NFfDfoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mnv4TWM2OD1zMz6xPVM4KM7:TR?=	MmLkV2FPT0WU
NCI-H2452	M2qwb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHjzRpdKSzVyPUGzMlIyPzVizszN	MVrTRW5ITVJ?
CAPAN-1	NF6xRVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHTUXJpKSzVyPUGzMlU2OTRizszN	M3ftO3NCVkeHUh?=
NCI-H2009	Mn3aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXLkN4tHUUN3ME2xN{42QTF7IN88US=>	NW\uV3FEW0GQR1XS
SF268	M1\tNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NW\q[nVTUUN3ME2xN{43OzJ4IN88US=>	MWLTRW5ITVJ?
GCIY	NXzPZ5E5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{S5[mlEPTB;MUOuOlkzPyEQvF2=	NG\1enZUSU6JRWK=
OS-RC-2	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFfCcXdKSzVyPUGzMlk2ODFizszN	M1vUZXNCVkeHUh?=
GCT	M2PtO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmLHTWM2OD1zMz65Olk4KM7:TR?=	MUjTRW5ITVJ?
NB17	M{jIOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1f1dmlEPTB;MUSuNFg2KM7:TR?=	NHvyVYVUSU6JRWK=
NCI-H2030	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVvJR\|UxRTF2LkG0OlUh\|ryP	NIe4W3RUSU6JRWK=
HC-1	NWfXcGlCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlvVTWM2OD1zND6yNFg4KM7:TR?=	NXe3[\|F5W0GQR1XS
QIMR-WIL	M1f4c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml7RTWM2OD1zND6zOFEzKM7:TR?=	M{DC[XNCVkeHUh?=
Capan-2	M3jpRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUD3T5cxUUN3ME2xOE4{PzF2IN88US=>	NHfPWopUSU6JRWK=
BALL-1	NFXJ[\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYnWVHBTUUN3ME2xOE41PjZ3IN88US=>	NH;wVo5USU6JRWK=
LS-1034	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mmq4TWM2OD1zND62NVUzKM7:TR?=	MX7TRW5ITVJ?
U-118-MG	NFLWV25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWXJR\|UxRTF2Lk[zNUDPxE1?	NIDxV4FUSU6JRWK=
NCI-H630	NE\mWZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmK0TWM2OD1zND62OVY5KM7:TR?=	MoX0V2FPT0WU
OVCAR-8	MoO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEe4RVVKSzVyPUG0MlczODFizszN	M2TOcXNCVkeHUh?=
NCI-H2347	NHTReHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUK3cnNWUUN3ME2xOE45OjNizszN	NHSwPGZUSU6JRWK=
BT-549	Mo\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUTJR\|UxRTF2LkiyPFQh\|ryP	M2\XdnNCVkeHUh?=
LB831-BLC	NFK4bZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYDJR\|UxRTF2Lki5N\|Qh\|ryP	NWf2SllkW0GQR1XS
NCI-H661	NX7ncop{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWjYdot2UUN3ME2xOE46PTlizszN	NUXnT4NHW0GQR1XS
MKN7	MmfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoexTWM2OD1zNT6wNFk{KM7:TR?=	NHL0eXFUSU6JRWK=
U-87-MG	NEfzNXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3\iSWlEPTB;MUWuNFg6PyEQvF2=	MkPPV2FPT0WU
OVCAR-4	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NILFR3VKSzVyPUG1MlE1OjRizszN	NFnYT\|NUSU6JRWK=
OE33	MoLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NW\2Wop5UUN3ME2xOU4yPzFzIN88US=>	MUPTRW5ITVJ?
EC-GI-10	M{iwUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUfYTWFWUUN3ME2xOU4zOzV5IN88US=>	Mnf6V2FPT0WU
AM-38	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnvmTWM2OD1zNT6yO\|E4KM7:TR?=	NHLESmtUSU6JRWK=
NCI-H1563	NXrRXldtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NU\LdWRIUUN3ME2xOU4{PDlizszN	NGDSbGJUSU6JRWK=
SCC-4	MnrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoHrTWM2OD1zNT60NVA{KM7:TR?=	M4Hm[XNCVkeHUh?=
Detroit562	NFK1WWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M13xSmlEPTB;MUWuOFU1PyEQvF2=	MlXIV2FPT0WU
PC-14	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlvaTWM2OD1zNT60PFY3KM7:TR?=	NETOOItUSU6JRWK=
ES3	NFzXbJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkHPTWM2OD1zNT61N\|Yh\|ryP	NGTwcVhUSU6JRWK=
OCI-AML2	M4TqN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NI[1[HBKSzVyPUG1Mlc3OTRizszN	Mn[zV2FPT0WU
LU-134-A	NIT4XWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NInpVFZKSzVyPUG1MlkxOThizszN	Mn24V2FPT0WU
SAS	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX3JR\|UxRTF3LkmzO\|Mh\|ryP	M4TCd3NCVkeHUh?=
TGBC11TKB	NGfQcGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVvJR\|UxRTF3Lkm0NVQh\|ryP	NGnnc\|BUSU6JRWK=
HOP-62	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYjJR\|UxRTF3Lkm1PVch\|ryP	MVrTRW5ITVJ?
G-401	M3rYVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M37JVWlEPTB;MUWuPVY1QSEQvF2=	NXzrNHFPW0GQR1XS
NCI-H28	M13qRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3raR2lEPTB;MU[uNFg2PiEQvF2=	NUnqb4g3W0GQR1XS
A204	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXzJR\|UxRTF4LkKwNFYh\|ryP	NYqzflF2W0GQR1XS
NCI-H1299	MmPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF62[49KSzVyPUG2MlIzQTFizszN	MoSxV2FPT0WU
VMRC-RCZ	NWHNTlFMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUfJR\|UxRTF4LkK1PVIh\|ryP	NUf6W\|lEW0GQR1XS
BxPC-3	M361cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHnTNlVKSzVyPUG2MlI5PTZizszN	M1nWeHNCVkeHUh?=
NCI-H2228	MnnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYrJR\|UxRTF4LkWxOVgh\|ryP	MUXTRW5ITVJ?
NCI-H23	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHLLToNKSzVyPUG2MlYxPzhizszN	NVT0W3htW0GQR1XS
NKM-1	NYnTfnZTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkfITWM2OD1zNz6wNVg6KM7:TR?=	MY\TRW5ITVJ?
KYSE-70	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXrXcIJMUUN3ME2xO{4zQDlizszN	M4HDOXNCVkeHUh?=
BB49-HNC	NYjO[WFxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn;STWM2OD1zNz61Olg3KM7:TR?=	NF7UPYdUSU6JRWK=
SCC-15	MnTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M33SXWlEPTB;MUeuPFQ4OyEQvF2=	NXnjOFB7W0GQR1XS
D-247MG	NH7FeIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVPSNFE{UUN3ME2xO{46OjR5IN88US=>	NH7KUVJUSU6JRWK=
BB30-HNC	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NI[xOYVKSzVyPUG4MlA{OThizszN	MnTKV2FPT0WU
CAL-85-1	NYCwN2pvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4HTRmlEPTB;MUiuNVgxQSEQvF2=	MUHTRW5ITVJ?
HT-3	NUPXSnhDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{K1VWlEPTB;MUiuN\|k4PyEQvF2=	MojxV2FPT0WU
KYSE-410	MoGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHnpSVJKSzVyPUG4MlQ2PzdizszN	Mk\LV2FPT0WU
SW982	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUD2fWFsUUN3ME2xPE42PjR7IN88US=>	M4HrOnNCVkeHUh?=
SW962	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVHIZZB[UUN3ME2xPE42PzB{IN88US=>	M2flSXNCVkeHUh?=
Ramos-2G6-4C10	M2G0fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4fnVGlEPTB;MUiuOVkzPyEQvF2=	NH[zRXhUSU6JRWK=
OC-314	Mn\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1rRZmlEPTB;MUiuO\|M5PCEQvF2=	NVKxTI17W0GQR1XS
LS-123	MnPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmXwTWM2OD1zOD63PVAyKM7:TR?=	M4DSWnNCVkeHUh?=
D-502MG	M{DycGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M163WGlEPTB;MUiuPFE{QSEQvF2=	M2\VbXNCVkeHUh?=
RO82-W-1	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV\TZ2t[UUN3ME2xPE45Ojh6IN88US=>	NIrD[3ZUSU6JRWK=
HuO9	NH31bHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWDERlZ1UUN3ME2xPU4yOzd7IN88US=>	M1vuOXNCVkeHUh?=
ETK-1	NUXyRldIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NG\rSYRKSzVyPUG5MlE5OjdizszN	MVHTRW5ITVJ?
SNU-387	M3TjZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIr6SWFKSzVyPUG5MlE5QDlizszN	Mli5V2FPT0WU
SW1573	MoraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn25TWM2OD1zOT6xPVY6KM7:TR?=	Mm\OV2FPT0WU
NTERA-S-cl-D1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml;tTWM2OD1zOT6yNFA4KM7:TR?=	MYrTRW5ITVJ?
SF126	MnXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWfUenJnUUN3ME2xPU4{PTB{IN88US=>	NHTJeXlUSU6JRWK=
Calu-3	MmHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVLJR\|UxRTF7LkSyN\|ch\|ryP	MUHTRW5ITVJ?
NCI-H1048	NHjacZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV3JR\|UxRTJyLkOyOlYh\|ryP	MlPmV2FPT0WU
NCI-H226	Mn\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3K1bWlEPTB;MkCuOFM6QSEQvF2=	M4XaW3NCVkeHUh?=
FTC-133	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1rYPGlEPTB;MkCuOFcxOyEQvF2=	M{P0dnNCVkeHUh?=
SF539	NXW5VmQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUjTc2E4UUN3ME2yNE42OTd{IN88US=>	NVLQW49rW0GQR1XS
TE-6	NHLnNVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV\u[\|FDUUN3ME2yNE45ODZ5IN88US=>	M1SyfnNCVkeHUh?=
UMC-11	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmLJTWM2OD1{MD65NVY1KM7:TR?=	MnvLV2FPT0WU
Becker	NHToOlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NITTbFBKSzVyPUKxMlEyOThizszN	NVzaVZRzW0GQR1XS
KP-4	M33OZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYjKPWhOUUN3ME2yNU4yOTl4IN88US=>	MWXTRW5ITVJ?
ChaGo-K-1	Mn3PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWLJR\|UxRTJzLkO2Nlch\|ryP	MV7TRW5ITVJ?
CFPAC-1	M3jQN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{XEOmlEPTB;MkGuN\|g2QCEQvF2=	Mo[yV2FPT0WU
A498	MlmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MULJR\|UxRTJzLkWzNVIh\|ryP	NH72VlJUSU6JRWK=
NCI-H1755	NUnHb5ltT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUDJR\|UxRTJzLk[3OFEh\|ryP	M2DETXNCVkeHUh?=
TI-73	M1LFSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3PpXGlEPTB;MkKuN\|I5KM7:TR?=	MX\TRW5ITVJ?
NCI-H441	M4rsOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYXJR\|UxRTJ{LkW2PFkh\|ryP	NEDlUWdUSU6JRWK=
CaR-1	NFXHPHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIXwVVJKSzVyPUKzMlAzOTNizszN	MkDOV2FPT0WU
HCC1806	M{jDe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWjRcIlEUUN3ME2yN{4xPTh\|IN88US=>	NXnldow4W0GQR1XS
SNU-449	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXzURoVvUUN3ME2yN{4{OjlizszN	MVvTRW5ITVJ?
EKVX	M4XOfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX3IcXFtUUN3ME2yN{4{QTB7IN88US=>	MmD4V2FPT0WU
DMS-114	M3LvVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M17rSmlEPTB;MkOuOVc3PSEQvF2=	NULDe4t5W0GQR1XS
A704	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUTJR\|UxRTJ\|Lk[xNFMh\|ryP	NFHwPItUSU6JRWK=
LC-2-ad	M1rqNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV;JR\|UxRTJ\|Lk[xOFch\|ryP	NXSxPWx7W0GQR1XS
VM-CUB-1	NFO1PJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NY\PW2RGUUN3ME2yN{44OzRzIN88US=>	MYDTRW5ITVJ?
PC-3	NIXT[mdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4XjTWlEPTB;MkSuNFUzPiEQvF2=	M4PJenNCVkeHUh?=
HEL	M3;3Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mlv4TWM2OD1{ND6wPFY2KM7:TR?=	NWfrRVJXW0GQR1XS
ABC-1	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV36OnNuUUN3ME2yOE4zPzJ7IN88US=>	MkizV2FPT0WU
COLO-680N	Mn\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1PMPGlEPTB;MkSuOFc3PCEQvF2=	NXjLUXVlW0GQR1XS
MZ1-PC	M3vic2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWjJR\|UxRTJ2Lk[4O{DPxE1?	MkDTV2FPT0WU
NCI-H69	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX;JR\|UxRTJ2LkezOVQh\|ryP	NGTOXo5USU6JRWK=
TE-1	MoLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGDuOolKSzVyPUK1MlA1QTlizszN	M2HoV3NCVkeHUh?=
EW-3	MkLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYrSPXVGUUN3ME2yOU4yOTNizszN	MUPTRW5ITVJ?
PANC-08-13	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH7mbZpKSzVyPUK1MlgyODNizszN	NIfjTpBUSU6JRWK=
NMC-G1	NE\zVYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYnBUnlWUUN3ME2yOk4xODh6IN88US=>	M1uyT3NCVkeHUh?=
BT-20	NUnYXZh5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYHJR\|UxRTJ4LkS1OFMh\|ryP	M1;lSHNCVkeHUh?=
TGBC24TKB	NEPWfHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXHnO\|NOUUN3ME2yOk44OzNzIN88US=>	MVjTRW5ITVJ?
TE-11	M3\xPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH\WOoNKSzVyPUK2Mlk5QTVizszN	NHfHUVdUSU6JRWK=
ESS-1	M{fhTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWLFZW1zUUN3ME2yO{4{OjF4IN88US=>	MlT6V2FPT0WU
JVM-3	M2jXUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUHJR\|UxRTJ5Lk[0O\|Uh\|ryP	M4XuOnNCVkeHUh?=
C3A	NWLT[lZoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M371bWlEPTB;MkeuPFQ6PiEQvF2=	M4Oze3NCVkeHUh?=
MDA-MB-157	NGDZPIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmXGTWM2OD1{Nz64O\|U{KM7:TR?=	MVjTRW5ITVJ?
KLE	NV64RnNHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGfUSZNKSzVyPUK4MlExPThizszN	NXTzS2NxW0GQR1XS
ES1	Mn;3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnmxTWM2OD1{OD6xPFM5KM7:TR?=	NWn4dnl3W0GQR1XS
CAL-120	M1;rZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF[2N29KSzVyPUK4MlM6QTlizszN	NV7mNXhLW0GQR1XS
NCI-N87	NIHsPYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnvRTWM2OD1{OD61NVA2KM7:TR?=	M{WwN3NCVkeHUh?=
RPMI-8226	NHLITnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVvJR\|UxRTJ7LkG4OFMh\|ryP	NY\DVlYyW0GQR1XS
COR-L88	M1WzU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYTJR\|UxRTJ7LkK0NVkh\|ryP	NIm5c2ZUSU6JRWK=
UACC-893	NEHJOlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MULJR\|UxRTJ7LkOxN\|ch\|ryP	M2K2cnNCVkeHUh?=
C8166	NF;ybW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHS5SmhKSzVyPUK5Mlk6QTZizszN	MV3TRW5ITVJ?
J82	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkS1TWM2OD1\|MD64NVQ4KM7:TR?=	M2fheHNCVkeHUh?=
PFSK-1	MkPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVjJR\|UxRTNzLkC2OVkh\|ryP	NIHuV2VUSU6JRWK=
COLO-684	NGnKc3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn;oTWM2OD1\|MT60N\|c1KM7:TR?=	NGTCXYxUSU6JRWK=
CAL-72	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH:zTo9KSzVyPUOxMlU4OjlizszN	NEO1PVZUSU6JRWK=
SNB75	M3q1[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYTJR\|UxRTNzLki5O{DPxE1?	MkjtV2FPT0WU
MDA-MB-415	M3jB[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4fwR2lEPTB;M{GuPVc3OiEQvF2=	NEnJeFNUSU6JRWK=
SiHa	NXjseZc3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYr0NHFwUUN3ME2zNk41PzFzIN88US=>	MnnKV2FPT0WU
NCI-H1648	NWXLOFNIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHj4bY5KSzVyPUOyMlk{PDVizszN	M3jqcnNCVkeHUh?=
EFO-21	NEnLTFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVq3VIFlUUN3ME2zN{4xODVizszN	MkHVV2FPT0WU
HCC38	NHT4SYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHrTXmpKSzVyPUOzMlM5PDFizszN	MmDkV2FPT0WU
IA-LM	NFL5em9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWqyUHY4UUN3ME2zN{44QDh7IN88US=>	NHPtZYVUSU6JRWK=
CTV-1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGWySWZKSzVyPUOzMlk4QDZizszN	M3fu[3NCVkeHUh?=
NCI-H446	M3rKcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIrNR\|JKSzVyPUO0MlI3QDlizszN	Mm\0V2FPT0WU
IST-SL1	NHzPfmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWDJR\|UxRTN2Lke0NFgh\|ryP	MkX1V2FPT0WU
EW-22	NXzP[2NqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVrRcpBXUUN3ME2zOE44PzV7IN88US=>	NWX1WVB1W0GQR1XS
JEG-3	Ml7lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVf1dXdsUUN3ME2zOk4yPzZ4IN88US=>	NYm4bY5iW0GQR1XS
LU-65	NF;KdFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlHRTWM2OD1\|Nj6yPVg2KM7:TR?=	MV\TRW5ITVJ?
NCI-H596	NV;SSGtpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2TDc2lEPTB;M{[uPVU6OSEQvF2=	NITWPVNUSU6JRWK=
KNS-81-FD	NWnqb2RGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlXPTWM2OD1\|Nz6xOFUh\|ryP	MWfTRW5ITVJ?
NCI-H1793	M1npfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXO1Xm1UUUN3ME2zO{44ODh4IN88US=>	NIflcZNUSU6JRWK=
NCI-H460	NXHs[XRFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3GwWGlEPTB;M{iuNFg4OyEQvF2=	NHXHTXBUSU6JRWK=
MPP-89	NX3p[4Q2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXPJR\|UxRTN7LkW4PFYh\|ryP	MWPTRW5ITVJ?
D-542MG	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4nvVmlEPTB;M{muPFQ{PiEQvF2=	M125UnNCVkeHUh?=
JAR	M3y3dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnjITWM2OD12MD60O\|A2KM7:TR?=	NWL5NWd2W0GQR1XS
NCI-H209	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIWwR4ZKSzVyPUSwMlY4PyEQvF2=	M2TlTXNCVkeHUh?=
G-402	NFHYV3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX7LVXZFUUN3ME20NU4{QTl\|IN88US=>	M2W1dnNCVkeHUh?=
IST-MES1	NVjMTppJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHqzV2VKSzVyPUSyMlE6OzVizszN	NInY[25USU6JRWK=
Daoy	NHLOS2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYjRe4V[UUN3ME20Nk42PDdzIN88US=>	M4TR[3NCVkeHUh?=
EW-11	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUDJR\|UxRTR\|LkGyNVEh\|ryP	M{frbXNCVkeHUh?=
Saos-2	NFXpZpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnvpTWM2OD12Mz6xOVM4KM7:TR?=	M1z1OHNCVkeHUh?=
no-10	MmjrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4jpXmlEPTB;NEOuNVcxOiEQvF2=	Ml\SV2FPT0WU
HCC1395	NGO5fWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlnMTWM2OD12Mz60OlQ1KM7:TR?=	M{TJXHNCVkeHUh?=
HCE-4	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVXJR\|UxRTR\|Lke2OlQh\|ryP	M1jxVHNCVkeHUh?=
EW-1	NVm3S45tT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWDJR\|UxRTR\|LkiwOFkh\|ryP	NFHZXVVUSU6JRWK=
OCUB-M	M{H0N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3jaSmlEPTB;NESuN\|Y{QCEQvF2=	NYDwWIlIW0GQR1XS
IGR-1	NWHNOVlzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWfJR\|UxRTR2LkSxNVUh\|ryP	M3PyXXNCVkeHUh?=
NCI-H1838	M{jzfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXjJR\|UxRTR2LkSzOFkh\|ryP	MXjTRW5ITVJ?
NCI-H2405	M4LVRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUTJR\|UxRTR2LkWzOEDPxE1?	M1PoSXNCVkeHUh?=
GB-1	NIjrTHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWjJR\|UxRTR2Lke0OlMh\|ryP	MVPTRW5ITVJ?
MG-63	M3H2cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmnyTWM2OD12Nj6wOlk3KM7:TR?=	MoTZV2FPT0WU
KP-N-YN	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkjETWM2OD12Nj60Olc6KM7:TR?=	MXXTRW5ITVJ?
no-11	M3rp[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3fjPGlEPTB;NEeuNFI1PCEQvF2=	M3nqNXNCVkeHUh?=
SW948	NUCwbWkyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFLaWoNKSzVyPUS3MlM{PzdizszN	MX3TRW5ITVJ?
CAMA-1	M4rOT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUm1OItUUUN3ME20O{4{PDN6IN88US=>	M37Jb3NCVkeHUh?=
HCC1187	NFSzSW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnXMTWM2OD12Nz61NUDPxE1?	NG\qS4pUSU6JRWK=
D-392MG	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYLJO\|NZUUN3ME20O{43PTF4IN88US=>	NX:0SpIxW0GQR1XS
647-V	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUnJR\|UxRTR7LkO0NVQh\|ryP	NF;Od\|JUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-ERK1/2 / ERK1/2 ; PubMed: 21762482 BMC Neurosci Effect of PD184352 on phosphorylation of ERK1/2 in sympathetic neurons. Immunoblots were performed with whole cell extracts from sympathetic neurons maintained in the presence of NGF and left untreated or treated with PD184352 at 0.1, 1, 2 or 10 μM for 16 hours. Antibodies to detect total ERK1/2 and phospho-ERK1/2 were used. p-ERK5 / ERK5 ; PubMed: 21762482 BMC Neurosci Effect of PD184352 on phosphorylation of ERK5 in sympathetic neurons.	21762482
Growth inhibition assay	Cell viability; PubMed: 29989268 Cancer Sci Relative viability of DU145CR cells treated with PD184352 was significantly less than that of DU145 cells in WST assay.	29989268

In vivo

Oral dosing of CI-1040 impairs the growth of colon tumor xenografts of mouse and human with a wide dose range of 48-200 mg/kg per dose, but not of P388 leukemia. ^[1] CI-1040 inhibits the tumor xenografts from PTC cells carrying a BRAF mutation with 31.3% reduction, carrying the RET/PTC1 rearrangement with 47.5% reduction than in untreated (vehicle) mice after 3 weeks of oral administration (300 mg/kg/d). No toxic effects are observed in any mice when they are treated with CI-1040. ^[2] Transient exposure of mammary tumors to CI-1040 and UCN-01 causes tumor cell death in vivo and prolonged suppression of tumor regrowth. Combined treatment with CI-1040 (25 mg/kg) and UCN-01 (0.1-0.2 mg/kg) significantly reduces MDA-MB-231, and largely abolishs MCF7 tumor growth in implanted athymic mice, while either single treatment has no significant activity. The drug combination leads to profound tumor cell death which correlates with a reduction in the phosphorylation of ERK1/2 and the immuno-reactivity of Ki67 and of CD31. ^[5]

Protocol

Kinase Assay: ^[2]	- Collapse MEK1 Assay: MAP kinase is activated after phosphorylation by MEK; the activated MAP kinase subsequently phosphorylates myelin basic protein (MBP).Incorporation of ³²P into myelin basic protein (MBP) is assayed in the presence of glutathione S-transferase (GST) fusion proteins containing the 44-kDa MAPK (GST-MAPK) or the 45-kDa MEK (GST-MEK1). Assays are conducted in 50μL of 50 mM Tris, pH 7.4/10 mM MgCl₂ /2 mM EGTA/10 μM [γ-³²P]ATP containing 10 μg of GST-MEK1, 0.5 μg of GST-MAPK, and 40 μg of MBP. After incubation at 30°C for 15 minutes, reactions are stopped by addition of Laemmli SDS sample buffer. Phosphorylated MBP is resolved by SDS/10% PAGE. This screening effort leads to the discovery of several small-molecule inhibitors of MEK, i.e. CI-1040. Experiments assessing the order of addition shows that CI-1040 directly inhibits MEK1 with a 50% inhibitory concentration (IC50) of 17 nM, without affecting the activity of MAPK.
Cell Research: ^[1]	- Collapse Cell lines: Colon 26 carcinoma cells Concentrations: 0.1-10 μM Incubation Time: 24 hours Method: Cells are planted seeded in T-75 cm ² flasks and treated the next day for 24 hous with either DMSO or CI-1040. Single-cell suspensions are collected, and pellets are fixed in ice-cold ethanol (70%) for 30 minutes. After centrifugation of the samples, propidium iodide (50 μg/mL) and RNase (30 units/mL) are added to the pellets for 20 minutes at 37 °C. After filtration, samples are analyzed by flow cytometry. (Only for Reference)
Animal Research: ^[3]	- Collapse Animal Models: PTC cells in athymic mice Formulation: Cremophor EL–95% ethanol (50:50) and dilutes with water Dosages: 150 mg/kg Administration: Orally twice daily (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	96 mg/mL (200.55 mM)
	Ethanol	14 mg/mL (29.24 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 30% PEG400+0.5% Tween80+5% propylene glycol, pH 9 For best results, use promptly after mixing.	10 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download PD184352 (CI-1040) SDF

Molecular Weight	478.67
Formula	C₁₇H₁₄ClF₂IN₂O₂
CAS No.	212631-79-3
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

MEK Signaling Pathway Map

MEK Inhibitors with Unique Features

Selective MEK Inhibitor

Selumetinib (AZD6244) : MEK1-selective, IC50=14 nM.
Most Potent MEK Inhibitor

PD0325901 : MEK, IC50=0.33 nM,
FDA-approved MEK Inhibitor

Trametinib (GSK1120212) : Approved by FDA for BRAF V600E mutated metastatic melanoma.
Newest MEK Inhibitor

Binimetinib (MEK162, ARRY-162, ARRY-438162) : Potent inhibitor of MEK1/2 with IC50 of 12 nM.

Related MEK Products

Cobimetinib (GDC-0973, RG7420) ^New

Cobimetinib (GDC-0973, RG7420) is a potent and highly selective MEK1 inhibitor with IC50 of 4.2 nM, showing more than 100-fold selectively for MEK1 over MEK2 and showed no significant inhibition when tested against a panel of more than 100 of serine-threonine and tyrosine kinases. Phase 3.
BI-847325 ^New

BI-847325 is an orally bioavailable, and selective dual MEK/Aurora kinase inhibitor with IC50 of 3 nM, 25 nM, 15 nM, 25 nM, and 4 nM for Xenopus laevis Aurora B, human Aurora A and Aurora C, as well as human MEK1 and MEK2, respectively. Phase 1.
GDC-0623 ^New

GDC-0623 is a potent and ATP-uncompetitive MEK1 inhibitor with K_i of 0.13 nM. Phase 1.
Trametinib (GSK1120212)

Trametinib (GSK1120212) is a highly specific and potent MEK1/2 inhibitor with IC50 of 0.92 nM/1.8 nM in cell-free assays, no inhibition of the kinase activities of c-Raf, B-Raf, ERK1/2.

Features:More potent than PD0325901 or AZD6244.
PD0325901

PD0325901 is a selective and non ATP-competitive MEK inhibitor with IC50 of 0.33 nM in cell-free assays, roughly 500-fold more potent than CI-1040 on phosphorylation of ERK1 and ERK2. Phase 2.
Selumetinib (AZD6244)

Selumetinib (AZD6244) is a potent, highly selective MEK inhibitor with IC50 of 14 nM for MEK1 and Kd value of 530 nM for MEK2. It also inhibits ERK1/2 phosphorylation with IC50 of 10 nM, no inhibition to p38α, MKK6, EGFR, ErbB2, ERK2, B-Raf, etc. Phase 3.

Features:First MEK inhibitor being tested in Phase II clinical trials.
U0126-EtOH

U0126-EtOH is a highly selective inhibitor of MEK1/2 with IC50 of 0.07 μM/0.06 μM in cell-free assays, 100-fold higher affinity for ΔN3-S218E/S222D MEK than PD98059.

Features:A chemically synthesized and highly selective inhibitor of both MEK1 and MEK2.
PD98059

PD98059 is a non-ATP competitive MEK inhibitor with IC50 of 2 μM in a cell-free assay, specifically inhibits MEK-1-mediated activation of MAPK; does not directly inhibit ERK1 or ERK2.

Features:Does not inhibit c-Raf phosphorylated MEK1.
Binimetinib (MEK162, ARRY-162, ARRY-438162)

Binimetinib (MEK162, ARRY-162, ARRY-438162) is a potent inhibitor of MEK1/2 with IC50 of 12 nM in a cell-free assay. Phase 3.
Refametinib (RDEA119, Bay 86-9766)

Refametinib (RDEA119, Bay 86-9766) is a potent, ATP non-competitive and highly selective inhibitor of MEK1 and MEK2 with IC50 of 19 nM and 47 nM, respectively.

Choose Your Country or Region

By Signaling Pathways

By product type

PD184352 (CI-1040)

Cited by 69 Publications

Purity & Quality Control

Choose Selective MEK Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download PD184352 (CI-1040) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

MEK Signaling Pathway Map

MEK Inhibitors with Unique Features

Related MEK Products

Choose Your Country or Region

By Signaling Pathways

By product type

PD184352 (CI-1040)

Cited by 69 Publications

Purity & Quality Control

Choose Selective MEK Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download PD184352 (CI-1040) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

MEK Signaling Pathway Map

MEK Inhibitors with Unique Features

Related MEK Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)